Integrated analysis of two randomized controlled trials of a digital therapeutic for episodic migraine prevention.

Shaheen E Lakhan^1,2, Mariya Petrova¹, Cassandra Snipes³, Alexander Kuka¹, Timothy Peters-Strickland¹, Olya Besedina¹, Laura Taraboanta¹, Viveca Livezey¹, Austin Speier¹, Merle Diamond⁴, Stewart J Tepper⁵

¹Click Therapeutics, Inc., New York, NY, USA.

²Boricua Bio, San Juan, PR, USA.

³Click Therapeutics, Inc., New York, NY, USA. csnipes@clicktherapeutics.com.

⁴Diamond Headache Clinic, Chicago, IL, USA.

⁵The New England Institute for Neurology and Headache, Stamford, CT, USA.

PubMed DOI

Abstract

Migraine is a highly disabling neurological condition that requires effective preventive treatment options. We developed CT-132, a digital therapeutic that delivers clinically validated cognitive behavioral therapeutic interventions, as an adjunct to existing migraine therapies. We evaluated CT-132 for the preventive treatment of migraine in two randomized controlled trials, and this report is an…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.